Compare EVTC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | NUVB |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2013 | N/A |
| Metric | EVTC | NUVB |
|---|---|---|
| Price | $28.06 | $4.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $35.80 | $11.38 |
| AVG Volume (30 Days) | 425.2K | ★ 3.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | $190.15 |
| Revenue Next Year | $6.86 | $62.54 |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $24.95 | $1.57 |
| 52 Week High | $38.56 | $9.75 |
| Indicator | EVTC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 44.62 |
| Support Level | $27.59 | $4.07 |
| Resistance Level | $30.25 | $5.55 |
| Average True Range (ATR) | 1.05 | 0.21 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 31.80 | 69.23 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions which derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. It derives maximum revenue from Latin America Payments and Solutions. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.